(eribulin mesylate

EISAI INDIA AND MYLAN ENTER INTO CO-EXCLUSIVE MARKETING AGREEMENTTO COMMERCILIZE TECERISĀ® THE SECOND ERIBULIN BRAND IN INDIA

TECERISĀ® aimed at expanding access to metastatic breast cancer patients in India Vishakhapatnam, September 29, 2019: Eisai Pharmaceuticals India Pvt.…

5 years ago

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…

5 years ago